Immunotherapy elicits mainly cytotoxic activities in the TME, especially tumor-infiltrating cytotoxic T lymphocytes, and dysregulated immune checkpoints (e.g., PD1, PD-L1, CTLA4, TIM3) enable immune invasion of tumor cells. Here, HAVCR2 is linked to neoplasm.